You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥(01672.HK):ASC47與司美格魯(月太)聯合療法安全性和耐受性良好
阿思達克 09-22 10:47
歌禮制藥-B(01672.HK)公佈旗下減重候選藥物ASC47與司美格魯(月太)聯用的臨牀研究結果,根據在美國開展的ASC47-103隨機雙盲研究,於治療第29天時,ASC47與司美格魯(月太)聯用在肥胖受試者中的減重效果較司美格魯(月太)單藥相對提升高達56.2%。聯合用藥組的胃腸道耐受性顯着優於單藥組,嘔吐發生率僅6.7%,遠低於單藥組的57.1%,所有甲狀腺功能檢查及心電圖結果均正常,未觀察到心率升高或QTc延長現象,認爲聯合療法安全性和耐受性良好。 該研究共入組28例肥胖受試者,評估三種不同劑量ASC47單次給藥與司美格魯(月太)聯用的安全性及療效。歌禮創始人、董事會主席兼首席執行官吳勁梓表示,該研究提供了重要的概念驗證數據,將爲後續的包括肥胖症和代謝相關脂肪性肝炎(MASH)等多種代謝疾病的IIb期聯合用藥研究設計提供關鍵依據。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account